SAB Biotherapeutics, Inc.
NASDAQ:SABS
2.55 (USD) • At close July 25, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2025 Q1 | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0.115 | 0 | 0.263 | 0.945 | 0.305 | 1.267 | 0.086 | 0 | 2.161 | 3.59 | 6.351 | 11.803 | 60.876 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0.786 | 0.967 | 1.022 | 1.985 | 0.944 | 0.985 | 0.892 | 0.923 | 0.924 | 0.91 | 0 | 0 | 60.284 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | -0.671 | 0 | -0.759 | -1.04 | -0.639 | 0.282 | -0.807 | 0 | 1.237 | 2.68 | 6.351 | 11.803 | 0.592 | -0.336 | -0.257 | 0 | 0 |
| Gross Profit Ratio
| 0 | -5.85 | 0 | -2.884 | -1.101 | -2.095 | 0.223 | -9.437 | 0 | 0.572 | 0.747 | 1 | 1 | 0.01 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 7.657 | 7.63 | 7.831 | 6.8 | 8.124 | 4.297 | 4.02 | 3.662 | 4.536 | 7.138 | 7.353 | 8.584 | 13.324 | 25.718 | 15.07 | 18.683 | 12.782 | 0 |
| General & Administrative Expenses
| 3.115 | 2.671 | 3.479 | 3.643 | 4.189 | 14.881 | 2.571 | 2.9 | 3.447 | 2.883 | 4.044 | 4.309 | 5.186 | 17.086 | 3.601 | 2.399 | 3.332 | 0 |
| Selling & Marketing Expenses
| 0 | 2.963 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 3.115 | 1.708 | 3.479 | 3.643 | 4.189 | 14.881 | 2.571 | 2.9 | 3.447 | 2.844 | 4.044 | 4.309 | 5.186 | 17.086 | 3.601 | 2.399 | 3.332 | 0.009 |
| Other Expenses
| 0 | -0.115 | 0 | -0.263 | -0.945 | -0.305 | -1.267 | -0.086 | -0.581 | -2.161 | -3.59 | -6.351 | -11.803 | -61.58 | -14.681 | -18.21 | -16.928 | 0 |
| Operating Expenses
| 10.772 | 9.338 | 11.309 | 9.443 | 10.35 | 18.874 | 5.323 | 5.67 | 7.402 | 7.86 | 7.807 | 6.543 | 6.707 | 12.689 | 0.336 | 2.873 | -0.814 | 0.009 |
| Operating Income
| -10.772 | -10.009 | -11.309 | -10.202 | -11.391 | -18.874 | -5.323 | -6.477 | -7.402 | -7.86 | -7.807 | -6.543 | -6.707 | -12.689 | -0.336 | -2.873 | 0.814 | -0.009 |
| Operating Income Ratio
| 0 | -87.264 | 0 | -38.771 | -12.059 | -61.88 | -4.201 | -75.738 | 0 | -3.637 | -2.175 | -1.03 | -0.568 | -0.208 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 5.575 | -1.386 | 0.96 | 2.866 | 6.365 | -3.983 | 0.221 | -0.404 | 0.048 | 0.011 | 0.731 | 1.675 | 7.785 | -4.896 | 0.005 | -0.069 | 0.596 | 0 |
| Income Before Tax
| -5.197 | -11.395 | -10.349 | -7.335 | -5.026 | -22.857 | -5.102 | -6.881 | -7.354 | -7.849 | -7.076 | -4.868 | 1.078 | -17.585 | -0.331 | -2.942 | 1.41 | -0.009 |
| Income Before Tax Ratio
| 0 | -99.348 | 0 | -27.875 | -5.321 | -74.938 | -4.027 | -80.463 | 0 | -3.632 | -1.971 | -0.766 | 0.091 | -0.289 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.026 | 0 | -0.092 | 0.092 | 0 | -0.005 | 0 | 0 | 0 |
| Net Income
| -5.197 | -11.395 | -10.349 | -7.335 | -5.026 | -22.857 | -5.102 | -6.881 | -7.354 | -7.875 | -7.076 | -4.776 | 0.986 | -17.585 | -4.061 | -2.942 | 1.41 | -0.009 |
| Net Income Ratio
| 0 | -99.348 | 0 | -27.875 | -5.321 | -74.938 | -4.027 | -80.463 | 0 | -3.644 | -1.971 | -0.752 | 0.084 | -0.289 | 0 | 0 | 0 | 0 |
| EPS
| -0.56 | 2.45 | -1.12 | -0.79 | -0.54 | -3.86 | -0.97 | -1.36 | -1.46 | -1.56 | -1.6 | -1.11 | 0.23 | -4.11 | -0.075 | -0.68 | 0.32 | -0.002 |
| EPS Diluted
| -0.56 | 2.45 | -1.12 | -0.79 | -0.54 | -3.86 | -0.97 | -1.36 | -1.46 | -1.56 | -1.6 | -1.11 | 0.22 | -4.11 | -0.075 | -0.68 | 0.32 | -0.006 |
| EBITDA
| -4.349 | -10.538 | -9.305 | -6.187 | -2.965 | -21.834 | -4.047 | -5.913 | -6.338 | -6.838 | -6.096 | -4.016 | 1.828 | -16.146 | -3.568 | -2.567 | 1.762 | -0.009 |
| EBITDA Ratio
| 0 | -91.876 | 0 | -23.512 | -3.139 | -71.584 | -3.194 | -69.143 | 0 | -3.164 | -1.698 | -0.632 | 0.155 | -0.265 | 0 | 0 | 0 | 0 |